Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Exercise Capacity in Chronic Heart Failure
jRCTs031220571Recruiting
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in heart failure (HF) (2 arms). Primary endpoint: Change in peak oxygen consumption. Started Jan 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCTs031220571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220571.